Article
Biochemistry & Molecular Biology
Huili Zheng, Xiaofei Liang, Hongli Zhou, Tong Zhou, Xinhui Liu, Jialun Duan, Jin-ao Duan, Yue Zhu
Summary: In this study, the protective effect of Lycium barbarum polysaccharides (LBPs) on premature ovarian insufficiency (POI) was investigated in mice. LBPs improved ovarian reserve, regulated sex hormone levels, normalized estrous cycle, and increased offspring numbers in POI mice. Furthermore, LBPs had positive effects on gut microbiota and metabolism. These findings provide valuable support for the application of LBPs in the treatment of female ovarian function degeneration.
Article
Multidisciplinary Sciences
Muhammad Tanweer Khan, Chinmay Dwibedi, Daniel Sundh, Meenakshi Pradhan, Jamie D. Kraft, Robert Caesar, Valentina Tremaroli, Mattias Lorentzon, Fredrik Backhed
Summary: This study successfully co-isolated Faecalibacterium prausnitzii and Desulfovibrio piger and identified their symbiotic relationship in growth and butyrate production. By adapting Faecalibacterium prausnitzii to tolerate oxygen exposure, researchers developed a next-generation probiotic formulation.
Article
Immunology
Li-ting Jin, Ming-Zhi Xu
Summary: In obese patients, the connection between the gut microbiota and the onset of non-alcoholic fatty liver (NAFLD) is yet unknown. A study comparing the gut microbiota of obese individuals with and without NAFLD found a lower quantity of Faecalibacterium prausnitzii in the NAFLD group. Bacteroides, Clostridium leptum, and Clostridium butyricum were more prevalent in the NAFLD group, while Bacteroides, Clostridium butyricum, and F. prausnitzii were more prevalent in the simple obesity group. Lymphocytes and F. prausnitzii may play a role in determining the development of NAFLD in obese patients.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Genetics & Heredity
Florence Thirion, Finn Sellebjerg, Yong Fan, Liwei Lyu, Tue H. Hansen, Nicolas Pons, Florence Levenez, Benoit Quinquis, Evelina Stankevic, Helle B. Sondergaard, Thomas M. Dantoft, Casper S. Poulsen, Sofia K. Forslund, Henrik Vestergaard, Torben Hansen, Susanne Brix, Annette Oturai, Per Soelberg Sorensen, Stanislav D. Ehrlich, Oluf Pedersen
Summary: This study found significant differences in the gut microbiota of patients with multiple sclerosis, which are directly associated with inflammation markers. In treatment-naive cases, the bacterial richness is positively linked to disease activity. However, two symbiotic bacterial species that produce beneficial immune-modulating compounds were found in non-disease-active cases, providing a rationale for testing these bacteria as adjunct therapeutics in future clinical trials.
Review
Medicine, General & Internal
Yilun Wang, Jie Wei, Weiya Zhang, Michael Doherty, Yuqing Zhang, Haibin Xie, Wei Li, Ning Wang, Guanghua Lei, Chao Zeng
Summary: Dysbiosis in gut microbiota may be associated with the occurrence or development of rheumatic diseases. The review of existing evidence suggests that there is a decrease in alpha-diversity indices in rheumatic diseases, but the specific associations with different rheumatic diseases are inconsistent. Alterations in certain microbial populations in the gut may be related to rheumatic diseases.
Article
Multidisciplinary Sciences
Laura Sanchis-Artero, Juan Francisco Martinez-Blanch, Sergio Manresa-Vera, Ernesto Cortes-Castell, Marina Valls-Gandia, Marisa Iborra, Jose Maria Paredes-Arquiola, Maia Bosca-Watts, Jose Maria Huguet, Rafael Gil-Borras, Josefa Rodriguez-Morales, Xavier Cortes-Rizo
Summary: Intestinal dysbiosis plays a crucial role in the development of Crohn's disease (CD). A study conducted on CD patients undergoing anti-TNF treatment revealed significant changes in gut microbiota, with partial restoration observed in responders. The F.prausnitzii/E.coli ratio was identified as a reliable indicator of response to anti-TNF therapy in CD.
SCIENTIFIC REPORTS
(2021)
Article
Immunology
Francine Jotereau, Joudy Alameddine, Raluca Teusan, Annabelle Pedron, Nicolas Jouand, Frederic Altare, Emmanuelle Godefroy
Summary: In this study, a unique subset of Tregs called DP8 alpha Tregs was identified in humans. These Tregs secrete IL-10, co-express CD4 and CD8 alpha, and react against the symbiotic bacterium Faecalibacterium prausnitzii. They exhibit a mixed Tr1-like/cytotoxic CD4(+) T cell-profile and share master genes with mouse gut microbiota-induced Tregs. DP8 alpha Tregs possess potent cytotoxic, chemotactic, and IgA-promoting abilities. The discovery of their complete signature and novel functional properties provides important insights into their physiological roles and clinical applications in inflammatory bowel diseases.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Pharmacology & Pharmacy
Tatiani Uceli Maioli, Esther Borras-Nogues, Licia Torres, Sara Candida Barbosa, Vinicius Dantas Martins, Philippe Langella, Vasco Ariston Azevedo, Jean-Marc Chatel
Summary: Research has shown a direct link between the composition of the gut microbiota and the pathogenesis of obesity and diabetes. An obesity-inducing diet can lead to increased gut permeability and microbial dysbiosis, contributing to chronic inflammation and insulin resistance. Modulating the gut microbiota may be a potential treatment approach for these conditions.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Mika Sato, Yoshio Suzuki
Summary: This study investigated changes in the intestinal microbiota of ultramarathon runners and found a significant decrease in the abundance of butyrate-producing bacteria, which affects butyrate levels in the intestine and host immune function.
SCIENTIFIC REPORTS
(2022)
Article
Multidisciplinary Sciences
Ruiqing Wang, Xinyu Yang, Jinting Liu, Fang Zhong, Chen Zhang, Yuhong Chen, Tao Sun, Chunyan Ji, Daoxin Ma
Summary: This study demonstrates that the gut microbiota is associated with AML progression. Dysbiosis of the gut microbiota induced by antibiotic treatment accelerates AML progression in mice, while fecal microbiota transplantation reverses this process. Decreased levels of butyrate, produced by the gut microbiota (especially Faecalibacterium), are found in the feces of AML patients. However, gavage with butyrate or Faecalibacterium postpones AML progression in mice. Additionally, the study reveals that AML mice have damaged intestinal barriers, leading to increased leakage of lipopolysaccharide (LPS) into the blood. The increased LPS exacerbates leukemia progression in vitro and in vivo. Butyrate can repair intestinal barrier damage and inhibit LPS absorption in AML mice.
NATURE COMMUNICATIONS
(2022)
Article
Biochemistry & Molecular Biology
Lei Liu, Mehdi Sadaghian Sadabad, Giorgio Gabarrini, Paola Lisotto, Julius Z. H. von Martels, Hannah R. R. Wardill, Gerard Dijkstra, Robert E. Steinert, Hermie J. M. Harmsen
Summary: This study investigated the effects of riboflavin supplementation on gut microbiota, short-chain fatty acids, and gut hormones. The results revealed an increase in butyrate production and enhancement of microbial interaction network after riboflavin intervention. However, riboflavin supplementation did not impact the abundance of F. prausnitzii. Additionally, supplementation with 100 mg/d of riboflavin showed a trend of increased plasma insulin and GLP-1 levels.
ANTIOXIDANTS & REDOX SIGNALING
(2023)
Article
Immunology
Hong Ki Min, Hyun Sik Na, JooYeon Jhun, Seon-Yeong Lee, Sun Shim Choi, Go Eun Park, Jeong Su Lee, In Gyu Um, Seung Yoon Lee, Hochan Seo, Tae-Seop Shin, Yoon-Keun Kim, Jennifer Jooha Lee, Seung-Ki Kwok, Mi-La Cho, Sung-Hwan Park
Summary: In this study, we compared the gut microbiota of axSpA patients and healthy controls and found an association between specific gut microbiota and SpA pathogenesis. The results showed that axSpA patients had lower alpha-diversity and higher abundance of Bacteroides and Streptococcus, while Faecalibacterium prausnitzii, a butyrate-producing bacteria, was more abundant in healthy controls. Further experiments revealed that introducing F. prausnitzii or butyrate can reduce the polarization of CD4(+) IL-17A(+) T cells and the formation of osteoclasts, and decrease inflammation levels. Therefore, the reduced abundance of butyrate-producing microbes, especially F. prausnitzii, may be associated with axSpA pathogenesis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Jiang-nan Sun, Xiao-yi Yu, Bao Hou, Min Ai, Meng-ting Qi, Xin-yu Ma, Ming-jie Cai, Min Gao, Wei-wei Cai, Lu-lu Ni, Fei Xu, Yue-tao Zhou, Li-ying Qiu
Summary: Vaccarin, the main active component in traditional Chinese medicine Vaccaria, showed enhanced intestinal barrier function in T2DM mice by modulating gut microbiota and inhibiting the ERK/MLCK signaling pathway, resulting in anti-inflammatory effects.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Sergio E. Baranzini, iMSMS Consortium
Summary: The study found that the gut microbiome of multiple sclerosis patients is different from that of healthy controls. Specific microbial changes were observed in untreated MS patients. The therapeutic activity of interferon-b may be associated with upregulation of short-chain fatty acid transporters. These findings suggest a close association between the gut microbiome and multiple sclerosis risk, progression, and treatment response.
Article
Microbiology
Lu Wang, Gabriela Bravo-Ruiseco, Randolph Happe, Tao He, Jan Maarten van Dijl, Hermie J. M. Harmsen
Summary: The study reveals that unmodified vegetable oil in infant formula may affect the development of infant gut bacteria, causing inhibition of growth of bifidobacteria and faecalibacteria by CP.